[go: up one dir, main page]

IL117702A0 - Drug for hyperlipoproteinemia - Google Patents

Drug for hyperlipoproteinemia

Info

Publication number
IL117702A0
IL117702A0 IL11770296A IL11770296A IL117702A0 IL 117702 A0 IL117702 A0 IL 117702A0 IL 11770296 A IL11770296 A IL 11770296A IL 11770296 A IL11770296 A IL 11770296A IL 117702 A0 IL117702 A0 IL 117702A0
Authority
IL
Israel
Prior art keywords
hyperlipoproteinemia
drug
Prior art date
Application number
IL11770296A
Original Assignee
Tel Aviv Medical Center Resear
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tel Aviv Medical Center Resear filed Critical Tel Aviv Medical Center Resear
Priority to IL11770296A priority Critical patent/IL117702A0/en
Publication of IL117702A0 publication Critical patent/IL117702A0/en
Priority to PCT/IL1997/000085 priority patent/WO1997035576A1/en
Priority to AU22282/97A priority patent/AU2228297A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11770296A 1996-03-28 1996-03-28 Drug for hyperlipoproteinemia IL117702A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IL11770296A IL117702A0 (en) 1996-03-28 1996-03-28 Drug for hyperlipoproteinemia
PCT/IL1997/000085 WO1997035576A1 (en) 1996-03-28 1997-03-10 Use of isoniazid for the treatment of hyperlipoproteinemia
AU22282/97A AU2228297A (en) 1996-03-28 1997-03-10 Use of isoniazid for the treatment of hyperlipoproteinemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11770296A IL117702A0 (en) 1996-03-28 1996-03-28 Drug for hyperlipoproteinemia

Publications (1)

Publication Number Publication Date
IL117702A0 true IL117702A0 (en) 1996-07-23

Family

ID=11068709

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11770296A IL117702A0 (en) 1996-03-28 1996-03-28 Drug for hyperlipoproteinemia

Country Status (3)

Country Link
AU (1) AU2228297A (en)
IL (1) IL117702A0 (en)
WO (1) WO1997035576A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007427B1 (en) * 1998-09-30 2006-10-27 Варнер Ламберт Компани Method for preventing or delaying catheter-based revascularization
US6264960B1 (en) 1998-11-10 2001-07-24 Sander J. Robins Treatment of vascular events using lipid-modifying compositions
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
SI1355644T1 (en) 2001-01-26 2006-10-31 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DK1429756T3 (en) 2001-09-21 2007-03-19 Schering Corp Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20040092499A1 (en) 2002-11-06 2004-05-13 Schering Corporation Methods and therapeutic combinations for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756755A (en) 2003-03-07 2006-04-05 先灵公司 Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ATE418551T1 (en) 2003-03-07 2009-01-15 Schering Corp SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7220859B2 (en) 2005-01-12 2007-05-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
ATE421518T1 (en) 2005-02-10 2009-02-15 Bristol Myers Squibb Co DIHYDROQUINAZOLINONES AS 5HT MODULATORS
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
PE20091928A1 (en) 2008-05-29 2009-12-31 Bristol Myers Squibb Co HAVE HYDROXYSUSTITUTED PYRIMIDINES AS NON-BASIC MELANIN-CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
EP2411005A1 (en) 2009-03-27 2012-02-01 Bristol-Myers Squibb Company Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
WO2014039412A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
EP2892896B1 (en) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists

Also Published As

Publication number Publication date
AU2228297A (en) 1997-10-17
WO1997035576A1 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
IL117702A0 (en) Drug for hyperlipoproteinemia
PL340337A1 (en) Drugs
GB9602080D0 (en) Pharmaceutical compounds
DE69804447D1 (en) Lithographisches system
GB9700504D0 (en) Pharmaceutical compounds
HUP9901674A3 (en) New pharmaceutical combination
GB9609976D0 (en) Pharmaceutical compounds
GB9716244D0 (en) Pharmaceutical compounds
EP1003495A4 (en) Pharmaceutical compounds
GB9621789D0 (en) Pharmaceutical compounds
PL325324A1 (en) Heasting system
ZA979329B (en) Pharmaceutical compounds
GB9601544D0 (en) Pharmaceuticals
ZA98300B (en) Pharmaceutical compounds
GB9626151D0 (en) Pharmaceutical compounds
EG23684A (en) Pharmaceuticals
GB9715487D0 (en) Mearsurement system
GB9606745D0 (en) Pharmaceuticals
ZA971668B (en) Pharmaceutical compounds
GB9621365D0 (en) Pharmaceutical compounds
GB9613997D0 (en) Pharmaceutical compounds
GB9609299D0 (en) Pharmaceutical compounds
GB9717832D0 (en) Pharmaceutical compounds
GB9706302D0 (en) Pharmaceutical compounds
GB9705400D0 (en) Pharmaceutical compounds